# Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine

> **NCT02284035** · PHASE3 · COMPLETED · sponsor: **Juan A. Arnaiz** · enrollment: 75 (actual)

## Conditions studied

- AIDS

## Interventions

- **DRUG:** Raltegravir/3TC
- **DRUG:** EFV/TDF/FTC
- **DRUG:** ATV/r + TDF/FTC or DRV/r + TDF/FTC
- **DRUG:** DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC
- **DRUG:** EFV plus ABC/3TC or RPV/TDF/FTC
- **DRUG:** ATV/r plus ABC/3TC
- **DRUG:** DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC
- **DRUG:** RAL plus ABC/3TC
- **DRUG:** Other ART regimens

## Key facts

- **NCT ID:** NCT02284035
- **Lead sponsor:** Juan A. Arnaiz
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-27
- **Primary completion:** 2017-02-28
- **Final completion:** 2017-02-28
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02284035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02284035, "Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02284035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*